LifeMD to offer Novo Nordisk's Wegovy in oral form; shares jump

Shares in LifeMD jumped 12% on Monday, January 5, after the telemedicine platform announced an expansion of its partnership with Novo Nordisk whereby it will offer the weight-loss drug Wegovy in tablet form. The U.S. Food and Drug Administration approved the oral version shortly before Christmas.

LifeMD shares rose 12% on the Nasdaq on Monday to $3.90 per share. In morning trading on Tuesday, the stock has added a further 2% as of this writing.

The rally followed news of an expanded agreement with Novo Nordisk. Under the terms, patients using LifeMD’s telemedicine platform will be able to purchase Wegovy in tablet form. The FDA approved the oral version on December 22, making Wegovy the first obesity drug in its class available as a pill. Previously, such medications, like Eli Lilly’s competing Zepbound, have been available only as an injection.

Oral medications represent an important step forward in obesity treatment, LifeMD CEO Justin Schreiber said in comments cited in the company’s press release. Wegovy tablets are initially priced at roughly half the cost of injectable versions of both Wegovy and Zepbound. The pricing marks the start of a new race to attract overweight and obese patients, the FT reports.

LifeMD aims to capitalize on this shift. The company is featured on Novo Nordisk’s NovoCare and Wegovy websites via a “Find a Doctor” tool, a channel that LifeMD says complements its own patient-acquisition capabilities and supports longer-term expansion of access to the drug, Schreiber said.

In the 2025 third quarter, LifeMD posted a 13% year-over-year increase in revenue to $60.20 million, missing Wall Street expectations of $62.07 million. The company also lowered its 2025 revenue guidance but told investors that the introduction of oral obesity treatments could support a stronger business outlook in 2026.

LifeMD has seven analyst ratings of “buy” versus one “hold,” according to MarketWatch data. The average target price of $9.25 per share is roughly 2.4 times the latest closing price.